Obesity and metabolic syndrome in patients with schizophrenia;Obesidad y sídrome metabólico en pacientes con esquizofrenia

Psiquiatria Biologica

Volumn 12, Issue 2, 2005, Pages 39-45

  Villegas Martinez I ^a   Lopez Roman J ^a   Martinez Gonzalvez A B ^a   Villegas Garcia J A ^a  

^a CATHOLIC UNIVERSITY OF MURCIA   (Spain)

Author keywords

Metabolic syndrome; Obesity; Schizophrenia

Indexed keywords

AMPHETAMINE; BETA ENDORPHIN; CLOZAPINE; COCAINE; DYNORPHIN; ENDOCANNABINOID; ENKEPHALIN; GALANIN; GHRELIN; INSULIN; LEPTIN; NEUROPEPTIDE Y; OLANZAPINE; PROOPIOMELANOCORTIN;

HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MENTAL DISEASE; METABOLIC SYNDROME X; OBESITY; REVIEW; SCHIZOPHRENIA;

EID: 20744442431     PISSN: 11345934     EISSN: 15788962     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24:149-61.
2. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-20.
3. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101:277-88.
4. Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol. 1999;19:316-21.
5. Czobor P, Volavka J, Sheitman B. et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22:244-51.
6. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995;5:437-40.
7. Taylor DM, Mcaskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand. 2000;101: 416-32.
8. Bobes J, Rejas J, García-García M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res. 2003;62:77-88.
9. Beliard S, Valero R, Vialettes B. Atypical neuroleptics and diabetes. Diabetes Metab. 2003;29:296-9.
10. Slip E, Tranulis C, Legare N, Poulin MJ. Diabetes and schizophrenia, which links? Presse Med. 2003;32:1566-71.
11. Bralet MC, Yon V, Loas G, Noisette C. Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients. Encephale. 2000; 26:32-41.
12. Hannerz H, Borga P, Borritz M. Life expectancies for individuals with psychiatric diagnoses. Public Health. 2001;115: 328-37.
13. Joukamaa M, Heliovaara M, Knekt P, et al. Mental disorders and cause-specific mortality. Br J Psychiatr. 2001;179:498-502.
14. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatr. 2002;63:511.
15. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004;192:19-27.
16. Montout C, Casadebaig F, Lagnaoui R, et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res. 2002;57:147-56.
17. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatr. 2000;77:212-7.
18. Rosh A, Sampson BA, Hirsch CS. Schizophrenia as a cause of death. J Forensic Sci. 2003;48:164-7.
19. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatr. 2003;160:284-9.
20. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62:32-7.
21. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004; 66:51-7.
22. Le Fevre PD. Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism? Scott Med J. 2001;46:11-3.
23. Wetterling T, Pest S, Mussigbrodt H, Weber B. Bodyweight in inpatients with schizophrenia. Psychiatr Prax. 2004;31: 250-4.
24. Kraus T, Haack M, Schuld A. et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatr. 1999;156:312-4.
25. Paykel ES, Mueller PS, De la Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatr. 1973;123:501-7.
26. Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol. 1999;19:316-21.
27. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763-70.
28. Borrajo E. Aspectos actuales de la obesidad. An Esp Pediatr. 2002;56:1-11.
29. Prolo P, Wong ML, Licinio J. Leptin. Int J Biochem Cell Biol. 1998;30:1285-90.
30. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides. 1996;17:305-11.
31. Winnicki M, Somers VK, Accurso V, Phillips BG, Puato M, Palatini P, et al. Fish-rich diet, leptin, and body mass. Circulation. 2002;106:289-91.
32. Kraus T, Haack M, Schuld A, Hinze-Seich D, Pollmacher T. Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology. 2001;73:243-7.
33. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598-604.
34. Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatr. 2001;46:829-34.
35. Kivircik BB, Alptekin K, Caliskan S, Comlekci A, Oruk G, Tumuklu M, et al. Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:795-9.
36. Tsuda K, Nishio I. Leptin and membrane fluidity of erythrocytes in essential hypertension: an electron paramagnetic resonance investigation. Am J Hypertens. 2004;17:375-9.
37. Beltowski J, Wojcicka G, Marciniak A, Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci. 2004;74:2987-3000.
38. Calapai G, Corica F, Corsonello A, et al. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J Clin Invest. 1999;104:975-82.
39. Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull. 2003;29:393-7.
40. Weindruch R, Sohal RS. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N Engl J Med. 1997;337:986-94.
41. Mayeux R, Costa R, Bell K, et al. Reduced risk of Alzheimer's disease among individuals with low calorie intake. Neurology. 1999;59:S296-7.
42. Yu ZF, Mattson MP. Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J Neurosci Res. 1999;57:830-9.
43. Jump DB. Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci. 2004;41:41-78.
44. Villegas I, Villegas JA. Soporte nutricional al tratamiento convencional de las enfermedades del espectro esquizofrénico [accedido 25 Ago 2004]. Disponible en: http://www.onlinepsiquiatria.com/page_artinfo.php?artid= 14&PHPSESSID=69689bd4d2ffd4e35a7077a00576be4e
45. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatr. 2004;161:1334-49.
46. Aquila R, Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Companion. J Clin Psychiatr. 2000;2:20-3.
47. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatr. 2004;65:267-72.
48. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh. 2003;35:237-41.